Filter
Investigational Therapies
These compounds and their uses are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.
Showing results
Phase III
BREAST
GASTROINTESTINAL
GENITOURINARY
GYNECOLOGIC
HEAD/NECK
HEMATOLOGY
LUNG
MELANOMA
PAN TUMOR
SOLID TUMOR
Phase II
BREAST
GASTROINTESTINAL
GENITOURINARY
GYNECOLOGIC
HEAD/NECK
HEMATOLOGY
LUNG
MELANOMA
PAN TUMOR
SOLID TUMOR
Phase I
BREAST
GASTROINTESTINAL
Atezolizumab
(anti-PD-L1 MAb)
(RG7446)g
GASTROINTESTINAL
GENITOURINARY
HEMATOLOGY
SOLID TUMOR
GENITOURINARY
Atezolizumab
(anti-PD-L1 MAb)
(RG7446)g
GASTROINTESTINAL
GENITOURINARY
HEMATOLOGY
SOLID TUMOR
GYNECOLOGIC
HEAD/NECK
HEMATOLOGY
Atezolizumab
(anti-PD-L1 MAb)
(RG7446)g
GASTROINTESTINAL
GENITOURINARY
HEMATOLOGY
SOLID TUMOR
LUNG
MELANOMA
PAN TUMOR
SOLID TUMOR
Atezolizumab
(anti-PD-L1 MAb)
(RG7446)g
GASTROINTESTINAL
GENITOURINARY
HEMATOLOGY
SOLID TUMOR
aDeveloped in collaboration with Array
BioPharma. bIgnyta, Inc acquisition. cJoint
project with AbbVie. dDeveloped in collaboration with
Exelixis. eDeveloped in collaboration with Chugai.
fDeveloped in collaboration with BioNTech.
gDeveloped in collaboration with Xencor.
hDeveloped in collaboration with
Affirmed. IDeveloped in collaboration with Blueprint
Medicines.
Current as of February 4, 2021. The trial
information is taken from ClinicalTrials.gov.
Reference
- Roche. 2020 Results. February 4, 2021. https://www.roche.com/dam/jcr:e9d85f10-5ba5-4e8b-9535-eb8246b11641/en/irp210204.pdf. Accessed February 12, 2021.